JAC Advance Access originally published online on April 25, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 1377-1388
© 2003 The British Society for Antimicrobial Chemotherapy
Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment
1 Laboratory of Molecular Immunology of Infection and Inflammation, Pasteur Institute of Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cédex; 2 Department of Infectious Diseases, Northern AIDS Reference Center, Tourcoing Hospital, Tourcoing; 3 Department of Virology, Lille University Hospital Center, Lille, France
Received 27 November 2002; returned 26 February 2003; revised 6 March 2003; accepted 7 March 2003
In an effort to evaluate the potential of non-specific immunotherapy in restoring global immunity, we have examined the clinical tolerance and biological effects of a 6 week administration of the immunomodulator, murabutide, in chronically infected HIV-1 patients. Forty-two subjects, presenting weak immune reconstitution and ineffective virus suppression following long-term highly active antiretroviral therapy (HAART), were randomized to receive, or not, murabutide 7 mg/day on five consecutive days/week. Clinical and immunological parameters were monitored before and after the immunotherapy period. Administration of murabutide was generally well tolerated, although some grade III adverse events, reversible on treatment cessation, were observed. Interestingly, in comparison with pre-inclusion levels, at 1 week after the immunotherapy cycle, only murabutide recipients presented a significant increase in CD4 cells, platelet counts, and in the percentage of patients with undetectable viral loads (<50 copies/mL). Statistical significance between the two groups was only evident with the latter parameter. Some of these clinical changes were maintained even up to 12 weeks after murabutide administration, and were accompanied by an increased ability to mount cellular responses to active immunization with a recall antigen, and by a significant increase in the percentage of patients presenting positive lymphoproliferative responses to the viral antigen gp160. These results warrant further evaluation of extended periods or cycles of murabutide immunotherapy as adjunct to HAART.
Keywords: HIV, immunotherapy, murabutide, lymphoproliferation, chemokines
* Corresponding author. Tel: +33-3-20-87-72-90; Fax: +33-3-20-87-72-92; E-mail: georges.bahr{at}pasteur-lille.fr
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. C. Zink, J. Uhrlaub, J. DeWitt, T. Voelker, B. Bullock, J. Mankowski, P. Tarwater, J. Clements, and S. Barber Neuroprotective and Anti-Human Immunodeficiency Virus Activity of Minocycline JAMA, April 27, 2005; 293(16): 2003 - 2011. [Abstract] [Full Text] [PDF]
|
|